ProCE Banner Activity

Trastuzumab Deruxtecan for Brain Metastases in HER2-Positive Metastatic Breast Cancer: A Pooled Analysis of DESTINY-Breast01, 02, and 03 Trials

Conference Coverage

In this retrospective pooled analysis of the DESTINY-Breast01, 02, and 03 trials, trastuzumab deruxtecan was associated with an intracranial response rate of approximately 45% in patients with either stable or active brain metastases and demonstrated an acceptable safety profile in this population.

Released: November 01, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by an educational grant from AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Inc., Exelixis, Inc., Gilead Sciences, Inc., Lilly and Regeneron Pharmaceuticals, Inc.


Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis, Inc.

Gilead Sciences, Inc.


Regeneron Pharmaceuticals, Inc